Chemotherapy plus bevacizumab vs chemoimmunotherapy for metastatic colorectal cancer: Real-world analysis

Figure 1 Kaplan-Meier curve of original cohort. A: Kaplan-Meier curve of original cohort (progression-free survival); B: Kaplan-Meier curve of original cohort (overall survival). SOC: Standard-of-care; CIT: Chemoimmunotherapy.

Figure 2 Progression-free survival sensitivity analysis. A: After propensity score matching (PSM) analysis of progression-free survival (PFS) (ratio = 1); B: After PSM analysis of PFS (ratio = 2); C: After PSM analysis in PFS (ratio = 3); D: After PSM analysis of PFS (ratio = 4). SOC: Standard-of-care; CIT: Chemoimmunotherapy.

Figure 3 Overall survival sensitivity analysis. A: After propensity score matching (PSM) analysis of overall survival (OS) (ratio = 1); B: After PSM analysis of OS (ratio = 2); C: After PSM analysis of OS (ratio = 3); D: After PSM analysis of OS (ratio = 4). SOC: Standard-of-care; CIT: Chemoimmunotherapy.

Figure 4 Inverse probability of treatment weighting analysis. A: After inverse probability of treatment weighting analysis (progression-free survival); B: After inverse probability of treatment weighting analysis (overall survival). SOC: Standard-of-care; CIT: Chemoimmunotherapy.

Figure 5 Kaplan-Meier curves for progression-free survival. Progression-free survival according to alteration of neutrophil-to-lymphocyte ratio. A: After two cycles of immunotherapy; B: Systemic immune-inflammation index alteration; C: Lymphocyte-to-monocyte ratio alteration; D: Platelet-to-lymphocyte ratio alteration. HR: Hazard ratio; CI: Confidence interval; NLR: Neutrophil-to-lymphocyte ratio; SII: Systemic immune-inflammation index; LMR: Lymphocyte-to-monocyte ratio; PLR: Platelet-to-lymphocyte ratio.